[1. Singer M, Deutschman CS, Seymour CW, et al. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA. 2016;315:801-10. doi: 10.1001/ jama.2016.0287.]Open DOISearch in Google Scholar
[2. Copotoiu S-M, Copotoiu R. Much Ado About the New Definitions of Sepsis. J Crit Care Med. 2016;2:67-72. doi: 10.1515/jccm-2016-0015.]Open DOISearch in Google Scholar
[3. Rawal G, Kumar R, Yadav S, Singh A. Anemia in Intensive Care: A review of Current Concepts. J Crit Care Med. 2016;2:109-114. doi: 10.1515/jccm-2016-0017.]Open DOISearch in Google Scholar
[4. Semeraro N, Ammollo CT, Semeraro F, Colucci M. Sepsis, thrombosis and organ dysfunction. Thromb Res. 2012;129:290‑5. doi: 10.1016/j.thromres.2011.10.013.]Open DOISearch in Google Scholar
[5. Levi M. The coagulant response in sepsis and inflammation. Hamostaseologie. 2010;30:10-6.10.1055/s-0037-1617143]Search in Google Scholar
[6. Wiersinga WJ, Levi M, van der Poll T: Coagulation in Sepsis. In Abraham E, Singer M, editors: Mechanisms of Sepsis-Induced Organ Dysfunction and Recovery. Berlin, Heidelberg: Springer. 2007, pp. 273-85.10.1007/3-540-30328-6_19]Search in Google Scholar
[7. Levi M, Poll T. Coagulation in patients with severe sepsis. Semin Thromb Hemost. 2015;41:9-15. doi: 10.1055/s-0034-1398376.]Open DOISearch in Google Scholar
[8. Mackman N. The many faces of tissue factor. J Thromb Haemost. 2009;7 Suppl 1:136-9. doi: 10.1111/j.1538-7836.2009.03368.x.]Open DOISearch in Google Scholar
[9. Iba T, Nagaoka I, Boulat M. The anticoagulant therapy for sepsisassociated disseminated intravascular coagulation. Thromb Res. 2013;131:383-9. doi: 10.1016/j.thromres.2013.03.012.]Open DOISearch in Google Scholar
[10. Pawlinski R, Mackman N. Cellular sources of tissue factor in endotoxemia and sepsis. Thromb Res. 2010;125 Suppl 1:S70-3. doi: 10.1016/j.thromres.2010.01.042.]Open DOISearch in Google Scholar
[11. Camicia G, Pozner R, de Larranaga G. Neutrophil extracellular traps in sepsis. Shock. 2014;42:286-94. doi: 10.1097/ SHK.0000000000000221.]Open DOISearch in Google Scholar
[12. Allen KS, Sawheny E, Kinasewitz GT. Anticoagulant modulation of inflammation in severe sepsis. World J Crit Care Med. 2015;4:105-15. doi: 10.5492/wjccm.v4.i2.105.]Open DOISearch in Google Scholar
[13. Prakash S, Verghese S, Roxby D, et al. Changes in fibrinolysis and severity of organ failure in sepsis: a prospective observational study using point-of-care test--ROTEM. J Crit Care. 2015;30:264-70. doi: 10.1016/j.jcrc.2014.10.014.]Open DOISearch in Google Scholar
[14. Zeerleder S, Schroeder V, Hack CE, Kohler HP, Wuillemin WA. TAFI and PAI-1 levels in human sepsis. Thromb Res. 2006;118:205-12. doi: 10.1016/j.thromres.2005.06.007.]Open DOISearch in Google Scholar
[15. Georgescu A-M, Szederjesi J, Voidăzan S, et al. Soluble urokinase-type plasminogen activator receptor (suPAR) - a possible biomarker for bacteremia in sepsis. Romanian Review of Laboratory Medicine. 2015;23:59-73. doi: 10.1515/rrlm 2015-0002.]Open DOISearch in Google Scholar
[16. Fiusa MM, Carvalho-Filho MA, Annichino-Bizzacchi JM, De Paula EV. Causes and consequences of coagulation activation in sepsis: an evolutionary medicine perspective. BMC Med. 2015;13:105. doi: 10.1186/s12916-015-0327-2.]Open DOISearch in Google Scholar
[17. Toh CH, Alhamdi Y, Abrams ST. Current Pathological and Laboratory Considerations in the Diagnosis of Disseminated Intravascular Coagulation. Ann Lab Med. 2016;36:505-12. doi: 10.3343/alm.2016.36.6.505.]Open DOISearch in Google Scholar
[18. Robriquet L, Collet F, Tournoys A, et al. Intravenous administration of activated protein C in Pseudomonas-induced lung injury: impact on lung fluid balance and the inflammatory response. Respir Res. 2006;7:1-10. doi: 10.1186/1465-9921-7-41.]Open DOISearch in Google Scholar
[19. Mosnier LO, Zlokovic BV, Griffin JH. The cytoprotective protein C pathway. Blood. 2007;109:3161-72. doi: 10.1182/ blood-2006-09-003004.]Open DOISearch in Google Scholar
[20. Shaw AD, Vail GM, Haney DJ, Xie J, Williams MD. Severe protein C deficiency is associated with organ dysfunction in patients with severe sepsis.J Crit Care. 2011;26:539-45. doi: 10.1016/j. jcrc.2011.05.006.]Open DOISearch in Google Scholar
[21. Brunkhorst F, Sakr Y, Hagel S, Reinhart K. Protein C concentrations correlate with organ dysfunction and predict outcome independent of the presence of sepsis. Anesthesiology. 2007;107:15-23. doi: 10.1097/01.anes.0000267531.39410.d3.]Open DOISearch in Google Scholar
[22. Bernard GR, Vincent JL, Laterre PF, et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med. 2001;344: 699-709. doi: 10.1056/ nejm200103083441001.]Open DOISearch in Google Scholar
[23. Abraham E, Laterre P-F, Garg R, et al. Drotrecogin Alfa (Activated) for Adults with Severe Sepsis and a Low Risk of Death. N Engl J Med. 2005;353:1332-41. doi: 10.1056/NEJMoa050935.]Open DOISearch in Google Scholar
[24. Ranieri VM, Thompson BT, Barie PS, et al. Drotrecogin alfa (activated) in adults with septic shock. N Engl J Med. 2012;366:2055-64. doi: 10.1056/NEJMoa1202290.]Open DOISearch in Google Scholar
[25. Marti-Carvajal AJ, Sola I, Gluud C, Lathyris D, Cardona AF. Human recombinant protein C for severe sepsis and septic shock in adult and paediatric patients. Cochrane Database Syst Rev. 2012;12:Cd004388. doi: 10.1002/14651858.CD004388. pub6.]Open DOISearch in Google Scholar
[26. Casserly B, Gerlach H, Phillips GS, et al. Evaluating the use of recombinant human activated protein C in adult severe sepsis: results of the Surviving Sepsis Campaign. Crit Care Med. 2012;40:1417-26. doi: 10.1097/CCM.0b013e31823e9f45.]Open DOISearch in Google Scholar
[27. Dhainaut JF, Yan SB, Joyce DE, et al. Treatment effects of drotrecogin alfa (activated) in patients with severe sepsis with or without overt disseminated intravascular coagulation. J Thromb Haemost. 2004;2:1924-33. doi: 10.1111/j.1538-7836.2004.00955.x.]Open DOISearch in Google Scholar
[28. Iba T, Gando S, Thachil J. Anticoagulant therapy for sepsisassociated disseminated intravascular coagulation: the view from Japan. J Thromb Haemost. 2014;12:1010-9. doi: 10.1111/ jth.12596.]Open DOISearch in Google Scholar
[29. Aoki N, Matsuda T, Saito H, et al. A Comparative Double-Blind Randomized Trial of Activated Protein C and Unfractionated Heparin in the Treatment of Disseminated Intravascular Coagulation. Int J Hematol. 2002;75:540-7.10.1007/BF02982120]Search in Google Scholar
[30. Levi M, van der Poll T. The role of natural anticoagulants in the pathogenesis and management of systemic activation of coagulation and inflammation in critically ill patients. Semin Thromb Hemost. 2008;34:459-68. doi: 10.1055/s-0028-1092876.]Open DOISearch in Google Scholar
[31. Minnema MC, Chang AC, Jansen PM, et al. Recombinant human antithrombin III improves survival and attenuates inflammatory responses in baboons lethally challenged with Escherichia coli. Blood. 2000;95:1117-23.10.1182/blood.V95.4.1117.002k12_1117_1123]Search in Google Scholar
[32. Chappell D, Jacob M, Hofmann-Kiefer K, et al. Antithrombin reduces shedding of the endothelial glycocalyx following ischaemia/reperfusion. Cardiovasc Res. 2009;83:388-96. doi: 10.1093/cvr/cvp097.]Open DOISearch in Google Scholar
[33. Iba T, Gando S, Murata A, et al. Predicting the severity of systemic inflammatory response syndrome (SIRS)-associated coagulopathy with hemostatic molecular markers and vascular endothelial injury markers. J Trauma. 2007;63:1093-8. doi: 10.1097/01.ta.0000251420.41427.d3.]Open DOISearch in Google Scholar
[34. Warren BL, Eid A, Singer P, et al. Caring for the critically ill patient. High-dose antithrombin III in severe sepsis: a randomized controlled trial. JAMA. 2001;286:1869-78.10.1001/jama.286.15.1869]Search in Google Scholar
[35. Kienast J, Juers M, Wiedermann CJ, et al. Treatment effects of high-dose antithrombin without concomitant heparin in patients with severe sepsis with or without disseminated intravascular coagulation. J Thromb Haemost. 2006;4:90-7. doi: 10.1111/j.1538-7836.2005.01697.x.]Open DOISearch in Google Scholar
[36. Wiedermann CJ, Kaneider NC. A systematic review of antithrombin concentrate use in patients with disseminated intravascular coagulation of severe sepsis. Blood Coagul Fibrinolysis. 2006;17:521-6. doi: 10.1097/01. mbc.0000245302.18010.40.]Open DOISearch in Google Scholar
[37. Iba T, Saitoh D, Wada H, Asakura H. Efficacy and bleeding risk of antithrombin supplementation in septic disseminated intravascular coagulation: a secondary survey. Crit Care. 2014;18:497. doi: 10.1186/s13054-014-0497-x.]Open DOISearch in Google Scholar
[38. Iba T, Gando S, Saitoh D, et al. Efficacy and Bleeding Risk of Antithrombin Supplementation in Patients With Septic Disseminated Intravascular Coagulation. Clin Appl Thromb Hemost. 2016. doi: 10.1177/1076029616648405. [Epub ahead of print]]Open DOISearch in Google Scholar
[39. Gando S, Saitoh D, Ishikura H, et al. A randomized, controlled, multicenter trial of the effects of antithrombin on disseminated intravascular coagulation in patients with sepsis. Crit Care. 2013;17:R297. doi: 10.1186/cc13163.]Open DOISearch in Google Scholar
[40. Iba T, Saitoh D, Gando S, Thachil J. The usefulness of antithrombin activity monitoring during antithrombin supplementation in patients with sepsis-associated disseminated intravascular coagulation. Thromb Res. 2015;135:897-901. doi: 10.1016/j. thromres.2015.03.007.]Open DOISearch in Google Scholar
[41. Allingstrup M, Wetterslev J, Ravn FB, Moller AM, Afshari A. Antithrombin III for critically ill patients. Cochrane Database Syst Rev. 2016;2:Cd005370. doi: 10.1002/14651858.CD005370. pub3.]Open DOISearch in Google Scholar
[42. Iba T, Thachil J. Present and future of anticoagulant therapy using antithrombin and thrombomodulin for sepsis-associated disseminated intravascular coagulation: a perspective from Japan. Int J Hematol. 2016;103:253-61. doi: 10.1007/s12185-015-1904-z.]Open DOISearch in Google Scholar
[43. Oda S, Aibiki M, Ikeda T, et al. The Japanese guidelines for the management of sepsis. J Intensive Care. 2014;2:55. doi: 10.1186/s40560-014-0055-2.]Open DOISearch in Google Scholar
[44. King EG, Bauza GJ, Mella JR, Remick DG. Pathophysiologic mechanisms in septic shock. Lab Invest. 2014;94:4-12. doi: 10.1038/labinvest.2013.110.]Open DOISearch in Google Scholar
[45. Saito H, Maruyama I, Shimazaki S, et al. Efficacy and safety of recombinant human soluble thrombomodulin (ART-123) in disseminated intravascular coagulation: results of a phase III, randomized, double-blind clinical trial. J Thromb Haemost. 2007;5:31-41. doi: 10.1111/j.1538-7836.2006.02267.x.]Open DOISearch in Google Scholar
[46. Aikawa N, Shimazaki S, Yamamoto Y, et al. Thrombomodulin alfa in the treatment of infectious patients complicated by disseminated intravascular coagulation: subanalysis from the phase 3 trial. Shock. 2011;35:349-54. doi: 10.1097/ SHK.0b013e318204c019.]Open DOISearch in Google Scholar
[47. Vincent JL, Ramesh MK, Ernest D, et al. A randomized, doubleblind, placebo-controlled, Phase 2b study to evaluate the safety and efficacy of recombinant human soluble thrombomodulin, ART-123, in patients with sepsis and suspected disseminated intravascular coagulation. Crit Care Med. 2013;41:2069-79. doi: 10.1097/CCM.0b013e31828e9b03.]Open DOISearch in Google Scholar
[48. Hoppensteadt D, Tsuruta K, Cunanan J, et al. Thrombin generation mediators and markers in sepsis-associated coagulopathy and their modulation by recombinant thrombomodulin. Clin Appl Thromb Hemost. 2014;20:129-35. doi: 10.1177/1076029613492875.]Open DOISearch in Google Scholar
[49. Kato T, Sakai T, Kato M, et al. Recombinant human soluble thrombomodulin administration improves sepsis-induced disseminated intravascular coagulation and mortality: a retrospective cohort study. Thromb J. 2013;11:3. doi: 10.1186/1477-9560-11-3.]Open DOISearch in Google Scholar
[50. Yamakawa K, Aihara M, Ogura H, et al. Recombinant human soluble thrombomodulin in severe sepsis: a systematic review and meta-analysis. J Thromb Haemost. 2015;13:508-19. doi: 10.1111/jth.12841.]Open DOISearch in Google Scholar
[51. Maroney SA, Hansen KG, Mast AE. Cellular expression and biological activities of alternatively spliced forms of tissue factor pathway inhibitor. Curr Opin Hematol. 2013;20:403-9. doi: 10.1097/MOH.0b013e3283634412.]Open DOISearch in Google Scholar
[52. Lupu C, Herlea O, Tang H, Lijnen RH, Lupu F. Plasmin-dependent proteolysis of tissue factor pathway inhibitor in a mouse model of endotoxemia. J Thromb Haemost. 2013;11:142-8. doi: 10.1111/jth.12044.]Open DOISearch in Google Scholar
[53. Tang H, Ivanciu L, Popescu N, et al. Sepsis-induced coagulation in the baboon lung is associated with decreased tissue factor pathway inhibitor. Am J Pathol.. 2007;171:1066-77. doi: 10.2353/ajpath.2007.070104.]Open DOISearch in Google Scholar
[54. Abraham E, Reinhart K, Opal S, et al. Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomized controlled trial. JAMA. 2003;290:238-47. doi: 10.1001/jama.290.2.238.]Open DOISearch in Google Scholar
[55. Wunderink RG, Laterre PF, Francois B, et al. Recombinant tissue factor pathway inhibitor in severe community-acquired pneumonia: a randomized trial. Am J Respir Crit Care Med. 2011;183:1561-8. doi: 10.1164/rccm.201007-1167OC.]Open DOISearch in Google Scholar
[56. Polderman KH, Girbes AR. Drug intervention trials in sepsis: divergent results. Lancet. 2004;363:1721-3. doi: 10.1016/ s0140-6736(04)16259-4.]Open DOISearch in Google Scholar
[57. Levi M, Levy M, Williams MD, et al. Prophylactic heparin in patients with severe sepsis treated with drotrecogin alfa (activated). Am J Respir Crit Care Med. 2007;176:483-90. doi: 10.1164/rccm.200612-1803OC.]Open DOISearch in Google Scholar
[58. Jaimes F, De La Rosa G, Morales C, et al. Unfractioned heparin for treatment of sepsis: A randomized clinical trial (The HETRASE Study). Crit Care Med. 2009;37:1185-96. doi: 10.1097/CCM.0b013e31819c06bc.]Open DOISearch in Google Scholar
[59. Liu XL, Wang XZ, Liu XX, et al. Low-dose heparin as treatment for early disseminated intravascular coagulation during sepsis: A prospective clinical study. Exp Ther Med. 2014;7:604-8. doi: 10.3892/etm.2013.1466.]Open DOISearch in Google Scholar
[60. Wang C, Chi C, Guo L, et al. Heparin therapy reduces 28-day mortality in adult severe sepsis patients: a systematic review and meta-analysis. Critical care. 2014;18:563. doi: 10.1186/ s13054-014-0563-4.]Open DOISearch in Google Scholar
[61. Zarychanski R, Abou-Setta AM, Kanji S, et al. The efficacy and safety of heparin in patients with sepsis: a systematic review and metaanalysis. Crit Care Med. 2015;43:511-8. doi: 10.1097/ ccm.0000000000000763.]Open DOISearch in Google Scholar
[62. Houston BL, Dwivedi DJ, Grin P, et al. Biological Rational for the Use of Heparin in Septic Shock: Translational Data from the Halo Pilot RCT. Blood. 2015;126:2336.10.1182/blood.V126.23.2336.2336]Search in Google Scholar
[63. Wildhagen KC, Garcia de Frutos P, Reutelingsperger CP, et al. Nonanticoagulant heparin prevents histone-mediated cytotoxicity in vitro and improves survival in sepsis. Blood. 2014;123:1098-101. doi: 10.1182/blood-2013-07-514984.]Open DOISearch in Google Scholar
